Holzkirchen, Germany, March 23, 2018Sandoz, a Novartis division and the global leader in biosimilars, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for marketing authorization of infliximab, a proposed biosimilar to reference medicine infliximab** *.

The CHMP opinion recommends the proposed Sandoz biosimilar infliximab for the treatment of all indications of its reference medicine across gastroenterology, rheumatology and dermatology.

Living with inflammatory muscle Myositis

This was a global study done by investigators at Johns Hopkins, Seoul National University in Korea, and the Karolinska Institute in Sweden. They wanted to better understand how people living […]